Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. Summary
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
27.5(c) 27.9(c) 27.75(c) 29.7(c) 30.5(c) Last
22 893 17 394 3 794 43 868 33 521 Volume
-1.61% +1.45% -0.54% +7.03% +2.69% Change
More quotes
Financials
Sales 2021 99,4 M 120 M 120 M
Net income 2021 8,70 M 10,5 M 10,5 M
Net Debt 2021 37,4 M 45,2 M 45,2 M
P/E ratio 2021 -14,5x
Yield 2021 -
Sales 2022 0,77 M 0,93 M 0,93 M
Net income 2022 -52,1 M -63,0 M -63,0 M
Net Debt 2022 91,6 M 111 M 111 M
P/E ratio 2022 -11,5x
Yield 2022 -
Capitalization 437 M 529 M 529 M
EV / Sales 2021 4,77x
EV / Sales 2022 690x
Nbr of Employees 27
Free-Float 55,2%
More Financials
Company
Abivax mobilizes the body's natural immune machinery to treat patients with inflammatory diseases, viral infections and cancers. As a clinical phase company, Abivax is leveraging its antiviral and immune platforms to develop drug candidates leading to a cure for ulcerative colitis, Crohn's disease, and rheumatoid arthritis (ABX464), and liver cancer (ABX196). The Company's mission is to use its drug development... 
More about the company
Ratings of ABIVAX
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ABIVAX
06/07Abivax annonce les résultats de son Assemblée générale ordinaire annuelle et ..
DJ
06/07PRESS RELEASE  : Abivax releases the results of its June 4, 2021 ordinary annual..
DJ
06/07ABIVAX  : releases the results of its June 4, 2021 ordinary annual and extraordi..
EQ
05/27Affluent Medical lance son introduction en bourse -2-
DJ
05/27Affluent Medical launches its IPO on the -2-
DJ
05/25ABIVAX  : Surges 40% After Ulcerative Colitis Drug Demonstrates Efficacy In Mid-..
MT
05/24Abivax annonce d'excellents résultats -3-
DJ
05/24Abivax annonce d'excellents résultats -2-
DJ
05/24Abivax annonce d'excellents résultats d'efficacité et de tolérance d'ABX464 d..
DJ
05/24PRESS RELEASE : Abivax reports excellent efficacy -3-
DJ
05/24ABIVAX  : reports excellent efficacy and safety of ABX464 in phase 2b clinical t..
EQ
05/24PRESS RELEASE  : Abivax reports excellent efficacy -2-
DJ
05/24PRESS RELEASE  : Abivax reports excellent efficacy and safety of ABX464 in phase..
DJ
05/24ABIVAX  : Halts Trading of Shares Until Publication of Results of Mid-Stage Stud..
MT
05/24ABIVAX  : suspends trading of its shares until the publication of ABX464 Phase 2..
PU
More news
News in other languages on ABIVAX
06/07ABIVAX  : annonce les résultats de son Assemblée générale ordinaire annuelle et ..
06/07ABIVAX  : gibt die Ergebnisse seiner am 4. Juni abgehaltenen ordentlichen und au..
06/07Abivax gibt die Ergebnisse seiner am 4. Juni abgehaltenen ordentlichen und au..
05/27DGAP-NEWS : AFFLUENT MEDICAL kündigt Börsengang am -2-
05/26STOCK MARKET PARIS : Panne de volatilité
More news
Chart ABIVAX
Duration : Period :
ABIVAX Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 53,30 €
Last Close Price 30,50 €
Spread / Highest target 244%
Spread / Average Target 74,8%
Spread / Lowest Target -27,9%
EPS Revisions
Managers and Directors
NameTitle
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
ABIVAX-11.34%529
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416